PPPA (drug)

Last updated
PPPA
3-phenoxy-3-phenylpropan-1-amine.svg
Clinical data
ATC code
  • None
Identifiers
  • 3-Phenoxy-3-phenyl-1-propanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C15H17NO
Molar mass 227.307 g·mol−1
3D model (JSmol)
  • c1ccc(cc1)C(CCN)Oc2ccccc2
  • InChI=1S/C15H17NO/c16-12-11-15(13-7-3-1-4-8-13)17-14-9-5-2-6-10-14/h1-10,15H,11-12,16H2
  • Key:XYWLZHPZECQHMB-UHFFFAOYSA-N

PPPA, or 3-phenoxy-3-phenylpropan-1-amine, is a drug which is described as an antidepressant. [1] It was derived by Eli Lilly from the antihistamine diphenhydramine, a diphenylmethane derivative with additional properties as a selective serotonin reuptake inhibitor (SSRI), and has been the basis for the subsequent discovery of a number of other antidepressant drugs. [2] [3] [4]

Contents

List of PPPA derivatives

Structurally related drugs include dapoxetine, duloxetine, edivoxetine, femoxetine, paroxetine, reboxetine, and viloxazine, all of which act, similarly, as monoamine reuptake inhibitors, and most of which are, again similarly, antidepressants. [1] [3]

Zimelidine is an antidepressant and SSRI which was derived from the antihistamine pheniramine, which, similarly to its analogues brompheniramine and chlorpheniramine, possesses SNRI properties. [4] Fluvoxamine, another antidepressant and SSRI, was developed from the antihistamine tripelennamine, which possesses SNDRI actions. [6]

See also

References

  1. 1 2 3 4 Glennon RA, Dukat-Glennon M (2008). "Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 414–. ISBN   978-0-7817-6879-5.
  2. 1 2 3 López-Muñoz F, Álamo C (9 September 2011). "Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression". In López-Muñoz F, Álamo C (eds.). Neurobiology of Depression. CRC Press. pp. 132–. ISBN   978-1-4398-3850-1.
  3. 1 2 3 Childers Jr WE, Rotella DP (24 August 2010). "Selective Serotonin Reuptake Inhibitors for the Treatment of Depression". In Fischer J, Ganellin CR (eds.). Analogue-based Drug Discovery II. John Wiley & Sons. pp. 35, 282, 284. ISBN   978-3-527-63212-1.
  4. 1 2 3 Sneader W (31 October 2005). "Drugs Originating from the Screening of Organic Chemicals". Drug Discovery: A History. John Wiley & Sons. pp. 416–417. ISBN   978-0-470-01552-0.
  5. ↑ Brandt SD (9 February 2011). "CNS stimulants and CNS-active drugs affecting the serotonergic system". In Watson DG (ed.). Pharmaceutical Chemistry. Elsevier Health Sciences. pp. 1061–. ISBN   978-0-7020-4850-0.
  6. ↑ Healy D (1 June 2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. NYU Press. pp. 295–. ISBN   978-0-8147-7300-0.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.